Reduced Dissemination of Tumor Cells With Primary Ligation of the Vein in Patients With Lung Cancer

October 9, 2020 updated by: Lunxu Liu, West China Hospital

Reduced Dissemination of Tumor Cells With Primary Ligation of the Vein in Patients With Lung Cancer: A Multi-centre Randomized Controlled Trial

The purpose of this study is to assess the impact of the sequence of vessel interruption in lung cancer patients on tumor cell spread and patient survival by using peripheral blood circulating tumor cells.

Study Overview

Status

Unknown

Conditions

Intervention / Treatment

Detailed Description

Circulating tumor cells (CTCs) in the peripheral blood can be a biomarker to predict tumor recurrence and survival. Handling the tumor during a surgery may promote the release of CTCs into the bloodstream. Therefore, in a surgery of cancer, interruption of the vein before ligation of the artery may be justified. This multi-center randomized controlled trial is to assess the impact of the sequence of vessel interruption in lung cancer patients on tumor cell spread and patient survival by using peripheral blood CTCs.

Study Type

Interventional

Enrollment (Anticipated)

60

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • China
    • Sichuan
      • Chendu, Sichuan, China, 610041
        • West China Hospital, Sichuan University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 80 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. Patients with stage I-IV lung cancer eligible for surgery
  2. Patients undergoing the completely thoracoscopic lobectomy
  3. The nodule size was more than 2.5 cm
  4. Patients consenting for intraoperative blood sampling

Exclusion Criteria:

  1. Patients who underwent primary wedge resection and open lobectomy
  2. Patients who received neoadjuvant therapy before surgery

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Triple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Vein ligation first
During this procedure, patients undergo lobectomy with the pulmonary vein ligated first.
Procedure: Vein ligation first
During this procedure, patients undergo lobectomy with the pulmonary vein ligated first.
Active Comparator: Artery ligation first
During this procedure, patients undergo lobectomy with the pulmonary artery ligated first.
Procedure: Artery ligation first
During this procedure, patients undergo lobectomy with the pulmonary artery ligated first.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
The changes of the level of circulating tumor cells in the peripheral blood
Time Frame: Intraoperative
The changes of the level of circulating tumor cells in the peripheral blood before cutting the skin and after closing the chest
Intraoperative

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
3-year Progression-Free-Survival
Time Frame: From date of the recruitment, assessed up to 36 months
From the date of recruitment until the date of progression of lung cancer assessed up to 36 months
From date of the recruitment, assessed up to 36 months
Blood loss
Time Frame: During the surgery
Blood loss during the surgery
During the surgery
Operative time
Time Frame: During the surgery
Operative time during the surgery
During the surgery
Length of stay
Time Frame: From date of admission until the date of discharging or date of death from any cause in hospital, whichever came first, assessed up to 30 days
The length of patients staying in hospital from the date of checking in to the date of checking out
From date of admission until the date of discharging or date of death from any cause in hospital, whichever came first, assessed up to 30 days
Morbidity
Time Frame: Within 30 days after surgery
Complications resulting from surgery, such as pneumonia, air leak and arrhythmia.
Within 30 days after surgery

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

West China Hospital

Investigators

  • Principal Investigator: Lunxu Liu, M.D.,Ph.D., West China Hospital

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

December 1, 2016

Primary Completion (Actual)

May 31, 2018

Study Completion (Anticipated)

December 31, 2020

Study Registration Dates

First Submitted

February 5, 2018

First Submitted That Met QC Criteria

February 15, 2018

First Posted (Actual)

February 19, 2018

Study Record Updates

Last Update Posted (Actual)

October 12, 2020

Last Update Submitted That Met QC Criteria

October 9, 2020

Last Verified

October 1, 2020

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • TSCI005

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe